Contradicting the inflammatory hypothesis, they found lower serum levels in AD compared to healthy subjects and patients with vascular dementia and, treatment with acetylcholinesterase inhibitor (AChEI) had no influence on IL-15 concentrations in AD patients. Here, IL15 is linked to Alzheimer disease.